专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170362336A1 Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy 审中-公开
公开(公告)号：US20170362336A1
公开(公告)日：2017-12-21
申请号：US15609839
申请日：2017-05-31
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C07K16/30 , A61K39/00 , A61K39/395 , G01N33/574 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K7/08
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

2. 发明申请

US20140193417A1 Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy 有权
标题翻译：膜转运体NaPi2b（SCL34A2）抗体治疗表位，针对其的抗体和癌症治疗靶向
公开(公告)号：US20140193417A1
公开(公告)日：2014-07-10
申请号：US14037504
申请日：2013-09-26
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lloyd J. Old , Kenneth Lloyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： C07K16/18 , A61K39/00 , C07K7/08 , A61K39/395 , C07K14/47
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译：本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。还提供了产生免疫应答和治疗肿瘤和癌症的方法。提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

3. 发明申请

US20110129483A1 Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy 有权
标题翻译：用于抗体治疗的膜转运体NaPi2b（SCL34A1）表位，针对其的抗体和用于癌症治疗的靶标
公开(公告)号：US20110129483A1
公开(公告)日：2011-06-02
申请号：US12735576
申请日：2009-01-29
申请人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lioyd Old , Kenneth Lioyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
发明人： Gerd Ritter , Beatrice Yin , Anne Murray , George Mark , Lioyd Old , Kenneth Lioyd , Serhiy Souchelnytskiy , Ivan Gout , Valeriy Filonenko , Ramziya Kiyamova
IPC分类号： A61K39/395 , C07K16/18 , C12N15/13 , C12N1/21 , C12N1/19 , C12N5/07 , C12N5/04 , C07K14/435 , C07K7/08 , A61K39/00 , A61K38/00 , G01N33/53 , A61P35/00 , A61P37/00
CPC分类号： C07K16/3069 , A61K39/00 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/53 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , G01N33/57449 , G01N2333/705 , G01N2500/04
摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要翻译：本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。还提供了产生免疫应答和治疗肿瘤和癌症的方法。提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

4. 发明申请

US20100266643A1 PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P 审中-公开
标题翻译：血清淀粉酶的脉冲和鼻腔递送
公开(公告)号：US20100266643A1
公开(公告)日：2010-10-21
申请号：US12752627
申请日：2010-04-01
申请人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
发明人： W. Scott Willett , Richard J. Caimi , Lynne Anne Murray
IPC分类号： A61K38/16 , A61K9/14 , A61P11/00
CPC分类号： A61K38/1716 , A61K9/0043 , A61K9/0078
摘要： The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.
摘要翻译：本公开涉及将血清淀粉样蛋白P递送至呼吸系统的方法。还提供了包含适合于呼吸递送的SAP的药物组合物。

5. 发明申请

US20120183471A1 SPECIFIC BINDING PROTEINS AND USES THEREOF 有权
标题翻译：特异性结合蛋白及其用途
公开(公告)号：US20120183471A1
公开(公告)日：2012-07-19
申请号：US13201061
申请日：2010-02-17
申请人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
发明人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
IPC分类号： A61K39/395 , A61P35/00 , C12N1/19 , G01N33/574 , C12N5/10 , C12N1/21 , C07K16/30 , A61K51/00
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

6. 发明申请

US20110313230A1 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：特异性结合蛋白及其用途
公开(公告)号：US20110313230A1
公开(公告)日：2011-12-22
申请号：US13078764
申请日：2011-04-01
申请人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
发明人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
IPC分类号： A61N5/00 , A61K38/19 , A61P35/00 , A61K51/00 , A61K38/21 , A61K39/395 , A61K38/20
CPC分类号： A61K39/3955 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/30 , C07K16/4241 , C07K16/4258 , C07K16/4266 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

7. 发明申请

US20110076232A1 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：特异性结合蛋白及其用途
公开(公告)号：US20110076232A1
公开(公告)日：2011-03-31
申请号：US12890029
申请日：2010-09-24
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
IPC分类号： A61K51/10 , C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

8. 发明授权

US09233140B2 Treatment methods for hypersensitive disorders 有权
标题翻译：过敏性疾病的治疗方法
公开(公告)号：US09233140B2
公开(公告)日：2016-01-12
申请号：US12720847
申请日：2010-03-10
申请人： Lynne Anne Murray
发明人： Lynne Anne Murray
IPC分类号： A61K38/17
CPC分类号： A61K38/1716
摘要： The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
摘要翻译：目前治疗过敏性气道疾病的护理标准包括短期和长效β-激动剂，以及吸入或全身皮质类固醇，色甘酸和黄嘌呤，它们都具有有害副作用的潜力。本发明描述了用于治疗过敏性气道疾病和与过度Th2病理学相关的疾病的新的基于机械蛋白质的治疗方法。本发明涉及令人惊奇的发现，即血清淀粉样蛋白P（SAP）在治疗过敏性疾病中表现出治疗作用。

9. 发明授权

US09072798B2 Specific binding proteins and uses thereof 有权
标题翻译：特异性结合蛋白及其用途
公开(公告)号：US09072798B2
公开(公告)日：2015-07-07
申请号：US13201061
申请日：2010-02-17
申请人： Gerd Ritter , Anne Murray , George Mark , Christoph Renner
发明人： Gerd Ritter , Anne Murray , George Mark , Christoph Renner
IPC分类号： C07K16/28 , A61K51/10 , A61K39/395 , C07K16/30 , C07K16/42 , A61K39/00
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

10. 发明申请

US20100260781A1 TREATMENT METHODS FOR AUTOIMMUNE DISORDERS 审中-公开
标题翻译：自发性疾病治疗方法
公开(公告)号：US20100260781A1
公开(公告)日：2010-10-14
申请号：US12720845
申请日：2010-03-10
申请人： Lynne Anne Murray
发明人： Lynne Anne Murray
IPC分类号： A61K39/395 , A61K38/02 , A61K31/7088 , A61P3/10 , A61P19/02 , A61P37/06 , A61P17/06 , A61P27/02 , A61P1/00 , A61K35/12
摘要： The present invention provides methods and compositions for expanding T regulatory cells ex vivo or in vivo using one or more SAP agonists. The methods and compositions are useful in the treatment of autoimmune diseases and in preventing foreign graft rejection.
摘要翻译：本发明提供了使用一种或多种SAP激动剂离体或体内扩张T调节细胞的方法和组合物。该方法和组合物可用于治疗自身免疫性疾病和预防外来移植排斥反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式